Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Trial Results
Biotech
Ocugen eye disease gene therapy nabs underwhelming ph. 2 win
Cutting lesion size by 31% secured a trial victory, but didn't match the 54% figure set by a preliminary analysis.
Darren Incorvaia
Mar 24, 2026 10:40am
Genentech shreds RIPK1 inhibitor after ph. 2 failure
Mar 19, 2026 2:48pm
Aspen's Parkinson's cell therapy data plant seeds for ph. 3
Mar 18, 2026 9:00am
Ultragenyx gene therapy lessens ammonia levels in ph. 3
Mar 12, 2026 11:33am
Xenon epilepsy candidate 'blows away' ph. 3 expectations
Mar 9, 2026 10:55am
Nektar eczema asset 'checked all of the boxes' in phase 2
Feb 10, 2026 10:55am
